Background Clopidogrel as an adjunct to aspirin has improved outcomes after acute
coronary syndromes, but laboratory studies suggest a reduced antiplatelet effect when …

Objective To determine whether the treatment effect of apixaban versus warfarin differs with
increasing numbers of concomitant drugs used by patients with atrial fibrillation. Design Post …

Background Over the last decades important risk factors for gastrointestinal symptoms have
shifted, which may have changed its population prevalence. The aim of this study was to …

Background: The aminothiols homocysteine and, to a lesser extent, cysteine have been
associated with adverse cardiovascular outcome, whereas glutathione, as an antioxidant …

Despite dual antiplatelet therapy (DAPT), one-year event rates after acute coronary
syndrome (ACS) vary from 9–12%. The development of novel oral anticoagulants (NOAC) …

Dear Sir: We read with interest the article on the increased risk of gastrointestinal bleeding
(GIB), associated with the use of the novel oral anticoagulants (NOAC). 1 We compliment the …

TO THE EDITOR: We read Paciullo and colleagues' case report (1) with interest. Especially
during the coronavirus disease 2019 (COVID-19) pandemic, this information is crucial for …

Background High lipid content in the coronary artery vessel wall is predictive of future major
adverse cardiac events. The lipid core burden index (LCBI) as measured by near-infrared …

Purpose: In 2005 guidelines for resuscitation were altered to improve survival. However, in
studies comparing the former 2000 and current 2005 guidelines conflicting results have …

Dear Editor: With interest we read the special report by Arora et al regarding the use of
proton pump inhibitors for gastroduodenal damage related to nonsteroidal anti-inflammatory …